PLYX
What one share of Polaryx Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need.
Polaryx Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.15 |
|---|---|
| Cash and investments | $0.23 |
| Book value | $0.22 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$0.89 | — | −$0.08 | — | $0.11 |
| 2025 | — | −$0.20 | — | −$0.09 | — | $0.10 |